Genertec Universal Medical Group Company Limited (UMTAF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Genertec Universal Medical Group Company Limited (UMTAF) trades at $0.59 with AI Score 49/100 (Grade C). Genertec Universal Medical Group Company Limited operates in China, providing financing, advisory, and hospital management services. Market cap: $1.13B, Sector: Financial services.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for UMTAF: UMTAF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates UMTAF against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
UMTAF: the 1 perspectives are evenly split.
How is this calculated? →Genertec Universal Medical Group Company Limited (UMTAF) Financial Services Profile
Genertec Universal Medical Group Company Limited provides specialized financial and medical services in China, focusing on direct finance leasing, hospital management, and medical technology. With a P/E ratio of 4.84 and a dividend yield of 5.88%, the company operates within the financial services sector, serving hospitals and medical equipment suppliers.
What Is the Investment Thesis for UMTAF?
Genertec Universal Medical Group Company Limited presents a compelling investment case based on its strategic positioning within China's growing healthcare sector. With a P/E ratio of 4.84 and a dividend yield of 5.88%, the company offers potential value. Growth catalysts include the increasing demand for healthcare services and financing solutions in China. The company's ability to integrate financial and medical services provides a competitive edge. However, investors may want to evaluate the regulatory environment in China and the potential impact of economic fluctuations on the company's performance. The company's beta of 0.69 suggests lower volatility compared to the market.
Based on FMP financials and quantitative analysis
UMTAF Key Highlights
- Market capitalization of $1.13B indicates substantial company size within the financial services sector.
- P/E ratio of 4.84 suggests the company may be undervalued compared to its earnings.
- Profit margin of 15.2% demonstrates efficient profitability in its operations.
- Gross margin of 100.0% indicates strong pricing power or a unique accounting treatment.
- Dividend yield of 5.88% provides an attractive income stream for investors.
Who Are UMTAF's Competitors?
UMTAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AIFLF Aiful Corporation | $3.05 | +0.00% | $1.46B | 55 |
| ALEDY Allied Group Limited | $5.70 | +14.00% | $801.12M | 52 |
| BSMAF Bursa Malaysia Berhad | $2.18 | +0.00% | $1.76B | 48 |
| DEFTF DeFi Technologies Inc. | $3.60 | -6.25% | $1.18B | 63 |
| HMCBF Home Capital Group Inc. | $32.52 | +0.34% | $1.24B | 48 |
| ATLC Atlanticus Holdings Corporation | $96.44 | +0.04% | $1.46B | 71 |
| LPRO Open Lending Corporation | $3.13 | +0.64% | $370.35M | 68 |
| ATLCZ Atlanticus Holdings Corporation 9.25% Senior Notes due 2029 | $25.30 | +0.38% | $1.46B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are UMTAF's Key Strengths?
- Integrated financial and medical service offerings.
- Established presence in the Chinese healthcare market.
- Strong relationships with hospitals and medical institutions.
- Diversified revenue streams from finance, hospital management, and trading.
What Are UMTAF's Weaknesses?
- Reliance on the Chinese market.
- Exposure to regulatory changes in the healthcare and finance sectors.
- Potential credit risk from finance leasing activities.
- Limited international presence.
What Could Drive UMTAF Stock Higher?
- Expansion of hospital network through acquisitions and partnerships.
- Development and implementation of digital healthcare solutions.
- Growth in healthcare financing services.
- Potential policy changes in China's healthcare sector that could benefit the company in late 2026.
- Launch of new medical technology solutions in Q3 2026.
What Are the Key Risks for UMTAF?
- Increased competition from other financial and healthcare service providers.
- Economic downturn affecting healthcare spending.
- Changes in government regulations and policies in China.
- Potential for credit losses in finance leasing portfolio.
- Limited liquidity due to OTC market trading.
What Are the Growth Opportunities for UMTAF?
- Expansion of Hospital Network: Genertec Universal Medical Group can expand its hospital network through acquisitions and partnerships. The Chinese hospital market is projected to reach $1.5 trillion by 2030, offering significant growth potential. Expanding the hospital network would allow the company to serve a larger patient base and increase revenue from medical services. This strategy could be implemented over the next 3-5 years.
- Increased Focus on Medical Technology: Investing in and providing advanced medical technology solutions can drive growth. The global medical technology market is expected to reach $600 billion by 2028. By offering cutting-edge medical technology, Genertec Universal Medical Group can attract more hospitals and medical institutions as clients. This initiative can be rolled out within the next 2-3 years.
- Development of Digital Healthcare Solutions: Developing digital healthcare solutions, such as telemedicine and online consultation platforms, can enhance service delivery and reach a wider audience. The digital health market in China is growing rapidly, driven by increasing internet penetration and government support. Implementing these solutions can improve patient access to healthcare services and generate new revenue streams. This can be achieved in the next 1-2 years.
- Growth in Healthcare Financing: The demand for healthcare financing is increasing due to rising medical costs. Genertec Universal Medical Group can expand its financing and advisory services to meet this demand. The healthcare financing market in China is expected to grow at a CAGR of 10% over the next five years. By offering innovative financing solutions, the company can capture a larger share of this market. This expansion can occur over the next 3-5 years.
- International Expansion: Expanding operations to other countries in Asia can provide new growth opportunities. The healthcare markets in Southeast Asia and other regions are growing rapidly. By establishing a presence in these markets, Genertec Universal Medical Group can diversify its revenue streams and reduce its reliance on the Chinese market. This expansion can be planned and executed over the next 5-7 years.
What Opportunities Does UMTAF Have?
- Expansion into new healthcare markets in Asia.
- Development of digital healthcare solutions.
- Increased demand for healthcare financing.
- Acquisition of smaller hospitals and healthcare facilities.
What Threats Does UMTAF Face?
- Increased competition from other financial and healthcare service providers.
- Economic downturn affecting healthcare spending.
- Changes in government regulations and policies.
- Potential for credit losses in finance leasing portfolio.
What Are UMTAF's Competitive Advantages?
- Established relationships with hospitals and medical institutions in China.
- Expertise in both finance and healthcare management.
- Integrated service offerings combining financial and medical solutions.
- Strong understanding of the Chinese healthcare market and regulatory environment.
What Does UMTAF Do?
Founded in 1984 and headquartered in Beijing, China, Genertec Universal Medical Group Company Limited has evolved into a diversified financial and medical service provider. Initially known as Universal Medical Financial & Technical Advisory Services Company Limited, the company rebranded in July 2018 to reflect its expanded scope. The company operates through two primary segments: Finance and Advisory, and Hospital Group. The Finance and Advisory segment offers direct finance leasing, sale and leaseback, factoring, operating leases, and advisory services, catering to the financial needs of the healthcare industry. The Hospital Group segment focuses on providing medical services, hospital and healthcare management, import and export trading, and trading of medical-related goods. Genertec Universal Medical Group also provides medical technology, hospital digitalization, construction, management services, property management, and medical consulting services. Its customer base includes patients, hospitals, medical equipment suppliers, and other public institutions, solidifying its position as a key player in China's healthcare ecosystem.
What Products and Services Does UMTAF Offer?
- Provides direct finance leasing services to hospitals and medical institutions.
- Offers sale and leaseback arrangements for medical equipment.
- Engages in factoring services to manage accounts receivable for healthcare providers.
- Provides operating leases for medical facilities and equipment.
- Offers advisory services related to healthcare finance and management.
- Manages and operates hospitals and healthcare facilities.
- Trades medical-related goods and equipment.
- Provides medical technology and digitalization services.
How Does UMTAF Make Money?
- Generates revenue through interest income and fees from finance leasing and factoring services.
- Earns revenue from hospital management and medical service fees.
- Profits from the sale and trading of medical-related goods.
- Provides advisory services for a fee.
What Industry Does UMTAF Operate In?
Genertec Universal Medical Group Company Limited operates within China's expanding financial services and healthcare sectors. The demand for healthcare services and financing solutions is increasing due to an aging population and rising healthcare expenditure. The company competes with other financial and healthcare service providers in China. The company's integrated approach, combining financial and medical services, differentiates it from competitors. The Chinese healthcare market is characterized by government regulations and policies, which can impact the company's operations and growth prospects.
Who Are UMTAF's Key Customers?
- Hospitals and healthcare facilities seeking financing solutions.
- Medical equipment suppliers looking for leasing and factoring services.
- Patients receiving medical services at company-managed hospitals.
- Public institutions requiring healthcare management and consulting services.
ROE 12%Key Financial Metrics
Return on equity for Genertec Universal Medical Group Company Limited stands at 11.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.6%, showing how much profit it generates from its asset base. UMTAF trades at a trailing price-to-earnings ratio of 3.71, below the Financial Services sector average of ~18x. Its free cash flow yield is 50.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.64 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 27.0%, the inverse of the P/E and a quick read on earnings relative to price.
How Genertec Universal Medical Group Company Limited Is Valued
Genertec Universal Medical Group Company Limited carries a market capitalization of $1.13B, placing it in the small-cap category. Relative to its peer group, UMTAF's quantitative score of 49/100 is roughly in line with the peer average of 53/100.
F-Score 6/9Financial Health
Genertec Universal Medical Group Company Limited's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.41 places it in the grey zone, a middle ground that warrants monitoring.
UMTAF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Integrated financial and medical service offerings.
- Established presence in the Chinese healthcare market.
- Strong relationships with hospitals and medical institutions.
- Diversified revenue streams from finance, hospital management, and trading.
Bear Case
- Reliance on the Chinese market.
- Exposure to regulatory changes in the healthcare and finance sectors.
- Potential credit risk from finance leasing activities.
- Limited international presence.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
UMTAF Latest News
No recent news available for UMTAF.
UMTAF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for UMTAF.
Price Targets
Wall Street price target analysis for UMTAF.
UMTAF MoonshotScore
What does this score mean?
The MoonshotScore rates UMTAF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Wang Wenbing
Unknown
Information on Wang Wenbing's specific background and career history is not available in the provided data. However, as the leader managing 21089 employees, Wang Wenbing likely possesses extensive experience in the financial and healthcare sectors. Further research would be needed to ascertain specific details regarding their education, previous roles, and credentials.
Track Record: Due to the limited information available, Wang Wenbing's specific achievements and strategic decisions as leader of Genertec Universal Medical Group Company Limited cannot be detailed. Assessing their track record would require access to company performance data, strategic initiatives, and key milestones achieved under their leadership. Further investigation is needed to evaluate their impact on the company's growth and success.
UMTAF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Genertec Universal Medical Group Company Limited may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in UMTAF.
- Lower liquidity can lead to price volatility and difficulty in trading shares.
- Potential for fraud or manipulation is higher in the OTC market.
- Lack of regulatory oversight may expose investors to greater risks.
- Information asymmetry due to limited analyst coverage and public information.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive position.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC stocks.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- The company has been in operation since 1984.
- Genertec Universal Medical Group has a significant number of employees (21089).
- The company operates in a regulated industry (financial services and healthcare).
- The company has a market capitalization of $1.13B.
- The company has a dividend yield of 5.88%.
Genertec Universal Medical Group Company Limited Financial Services Stock: Key Questions Answered
What does Genertec Universal Medical Group Company Limited do?
Genertec Universal Medical Group Company Limited operates in two segments: Finance and Advisory and Hospital Group. The Finance and Advisory segment provides direct finance leasing, sale and leaseback, factoring, operating leases, and advisory services to hospitals and medical equipment suppliers. The Hospital Group segment engages in the provision of medical services, hospital and healthcare management, and trading of medical-related goods. The company serves patients, hospitals, medical equipment suppliers, and other public institutions in China.
What are the main risks for UMTAF?
The main risks for UMTAF include regulatory changes in China's healthcare and finance sectors, potential credit losses in its finance leasing portfolio, and increased competition from other financial and healthcare service providers. As an OTC-traded stock, UMTAF also faces risks related to limited liquidity and financial disclosure. An economic downturn could affect healthcare spending and impact the company's revenue. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for UMTAF?
Genertec Universal Medical Group Company Limited (UMTAF) holds an AI score of 49/100 (low). Not financial advice.
How frequently does UMTAF data refresh on this page?
UMTAF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven UMTAF's recent stock price performance?
Genertec Universal Medical Group Company Limited (UMTAF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated financial and medical service offerings. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider UMTAF overvalued or undervalued right now?
Valuing Genertec Universal Medical Group Company Limited (UMTAF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying UMTAF?
Before investing in Genertec Universal Medical Group Company Limited (UMTAF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding UMTAF to a portfolio?
Key strength of Genertec Universal Medical Group Company Limited (UMTAF): Integrated financial and medical service offerings. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending for UMTAF stock.
- OTC market investments carry higher risks.